isabelobrien, Author at European Medical Journal - Page 35 of 66

Illustration of a horizontal vaccine

Roche's twice-yearly MS injection wins FDA approval

The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

5 stars

Company reputation key to HCP prescribing decisions

New research shows that healthcare professionals consider a company’s leadership in a specific disease area and its overall reputation to be influential in prescribing decisions.

From congress to computer: Making on-demand video pop

Video is a powerful tool because it extends the reach of a live event, but does a recording ever live up to the event itself? Enter 3D interactive video.

Season 7 highlights: GOLD Medal Moments

The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7?

FDA lifts partial clinical hold on Rezolute hyperinsulinism treatment

The lift is based on new research showing that the previous adverse effects in laboratory rats may not have been caused by the drug itself.

New AI-focused RNA collaboration for Eli Lilly

Eli Lilly has entered into a research collaboration with Genetic Leap, a private company focused on AI, to advance the development of RNA-based genetic medicines.

NICE endorses Novartis’ take home drug for rare blood disorder

NICE recommends an oral therapy for adults with PNH, marking the 1000th medicine evaluated since its inception in 1999.

From data to decision-making: How AI will transform medical affairs

AI is becoming less of a buzzword for those in the pharma industry. For medical affairs teams, how will it transform the function’s future?

Sanofi's MS drug delivers surprising Phase III results

It’s been both a good and bad week for French pharmaceutical company Sanofi, as their MS drug candidate, received mixed trial results.

stamp of approval

Second mpox vaccine wins FDA approval

The FDA has formally approved Emergent BioSolutions’ smallpox and mpox vaccine for use in preventing the virus in people at high risk of infection.